Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 12/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 0.69 |
| ▸ | DRD2 | P14416 | 2/20 | 0.69 |
| ▸ | HTR2C | P28335 | 2/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL724547 | 1.00 | HDAC1 (1.00) | HDAC1KCNH2HTR2ADRD2HTR2C | |
| SCHEMBL727481 | 0.90 | HDAC1 (1.00) | HDAC1KCNH2HTR2ADRD2HTR2C | |
| SCHEMBL6865998 | 0.90 | HDAC1 (1.00) | HDAC1KCNH2HTR2ADRD2HTR2C | |
| SCHEMBL1486909 | 0.90 | HDAC1 (1.00) | HDAC1KCNH2HTR2ADRD2HTR2C | |
| SCHEMBL727482 | 0.90 | HDAC1 (1.00) | HDAC1KCNH2HTR2ADRD2HTR2C | |
| SCHEMBL721805 | 0.88 | HDAC1 (1.00) | HDAC1KCNH2HTR2ADRD2HTR2C | |
| SCHEMBL725420 | 0.88 | HDAC1 (1.00) | HDAC1KCNH2HTR2ADRD2HTR2C | |
| SCHEMBL1486874 | 0.86 | HDAC1 (1.00) | HDAC1KCNH2HTR2ADRD2HTR2C | |
| SCHEMBL1486872 | 0.86 | HDAC1 (1.00) | HDAC1KCNH2HTR2ADRD2HTR2C | |
| SCHEMBL30213 | 0.85 | HDAC1 (1.00) | HDAC1KCNH2HDAC6HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-03 | — | — | US | claimed |
| WO-2012025155-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885KCNH2 3415/4885HTR2A 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.